Feeds
3807 items (3807 unread) in 74 feeds
Acinar Cell Carcinoma
(40 unread)
Acinic Cell Carcinoma
(50 unread)
Adenoid Cystic Carcinoma
(96 unread)
Adrenal Gland Cancer
(350 unread)
Ampulla Of Vater
(53 unread)
Anal Cancer
(367 unread)
Angiosarcoma
(88 unread)
Appendix Cancer
(50 unread)
Bile Duct Cancer
(400 unread)
Brain and CNS
(353 unread)
Carcinoid
(144 unread)
Endocrine/Neuroendocrine
(453 unread)
Gall Bladder Cancer
(301 unread)
Hemangioendothelioma
(90 unread)
Hepatoblastoma
(50 unread)
Pancreas
(28 unread)
Phyllodes
(17 unread)
PMP and Mucinous Tumors
(22 unread)
Rhabdomyosarcoma
(212 unread)
Sarcoma
(643 unread)
Acinic Cell Carcinoma (50 unread)
Google - Acinic Cell Carcinoma
-
Gsk Blindedbysound 763-334 - Blinded By Sound
Posted: January 3rd, 2022, 5:46pm GMT
Gsk Blindedbysound 763-334 Blinded By Sound -
Uj Blindedbysound Gxr - Blinded By Sound
Posted: January 2nd, 2022, 6:09am GMT
Uj Blindedbysound Gxr Blinded By Sound -
Wjp Blindedbysound Tpd - Blinded By Sound
Posted: January 1st, 2022, 6:37pm GMT
Wjp Blindedbysound Tpd Blinded By Sound -
Mxa Blindedbysound 254-318 - Blinded By Sound
Posted: December 31st, 2021, 9:35pm GMT
Mxa Blindedbysound 254-318 Blinded By Sound -
Bgy Blindedbysound 224 - Blinded By Sound
Posted: December 31st, 2021, 3:43am GMT
Bgy Blindedbysound 224 Blinded By Sound -
Gzi Blindedbysound Exn - Blinded By Sound
Posted: December 31st, 2021, 2:30am GMT
Gzi Blindedbysound Exn Blinded By Sound -
Jgd Blindedbysound Q - Blinded By Sound
Posted: December 30th, 2021, 2:10pm GMT
Jgd Blindedbysound Q Blinded By Sound -
Zml Blindedbysound 354-595 - Blinded By Sound
Posted: December 29th, 2021, 5:07pm GMT
Zml Blindedbysound 354-595 Blinded By Sound -
400 patients and counting | Davison Index - Davisonindex
Posted: December 29th, 2021, 3:02am GMT
400 patients and counting | Davison Index Davisonindex -
400 patients and counting | Grand Blanc View - Grandblancview
Posted: December 29th, 2021, 3:02am GMT
400 patients and counting | Grand Blanc View Grandblancview -
Yf Blindedbysound 450-531 - Blinded By Sound
Posted: December 28th, 2021, 8:49pm GMT
Yf Blindedbysound 450-531 Blinded By Sound -
Ihl Blindedbysound 281-680 - Blinded By Sound
Posted: December 28th, 2021, 9:05am GMT
Ihl Blindedbysound 281-680 Blinded By Sound -
I Blindedbysound 7692533215 - Blinded By Sound
Posted: December 28th, 2021, 3:39am GMT
I Blindedbysound 7692533215 Blinded By Sound -
Fn Blindedbysound 512-700 - Blinded By Sound
Posted: December 28th, 2021, 11:44pm GMT
Fn Blindedbysound 512-700 Blinded By Sound -
Pj Blindedbysound Na - Blinded By Sound
Posted: December 26th, 2021, 8:17pm GMT
Pj Blindedbysound Na Blinded By Sound -
Htp Blindedbysound Dbs - Blinded By Sound
Posted: December 26th, 2021, 3:34pm GMT
Htp Blindedbysound Dbs Blinded By Sound -
Eo Blindedbysound 509 - Blinded By Sound
Posted: December 26th, 2021, 12:36pm GMT
Eo Blindedbysound 509 Blinded By Sound -
Sij Blindedbysound 540-763 - Blinded By Sound
Posted: December 25th, 2021, 7:37pm GMT
Sij Blindedbysound 540-763 Blinded By Sound -
F Blindedbysound Yz - Blinded By Sound
Posted: December 25th, 2021, 5:14am GMT
F Blindedbysound Yz Blinded By Sound -
Blindedbysound 682-540 - Blinded By Sound
Posted: December 25th, 2021, 4:09am GMT
Blindedbysound 682-540 Blinded By Sound -
W Blindedbysound Mez - Blinded By Sound
Posted: December 24th, 2021, 8:07pm GMT
W Blindedbysound Mez Blinded By Sound -
It Blindedbysound 9376870095 - Blinded By Sound
Posted: December 24th, 2021, 12:37pm GMT
It Blindedbysound 9376870095 Blinded By Sound -
Blindedbysound 833-387 - Blinded By Sound
Posted: December 23rd, 2021, 4:18pm GMT
Blindedbysound 833-387 Blinded By Sound -
Tav Blindedbysound O - Blinded By Sound
Posted: December 23rd, 2021, 3:54pm GMT
Tav Blindedbysound O Blinded By Sound -
Blindedbysound 250-417 - Blinded By Sound
Posted: December 23rd, 2021, 10:11pm GMT
Blindedbysound 250-417 Blinded By Sound -
Blindedbysound 717-584 - Blinded By Sound
Posted: December 22nd, 2021, 9:43pm GMT
Blindedbysound 717-584 Blinded By Sound -
400 Patients and Counting: The McLaren Proton Therapy Center Completes Another Milestone - McLaren Health Care
Posted: December 22nd, 2021, 6:00am GMT
-
Blindedbysound 419-781 - Blinded By Sound
Posted: December 22nd, 2021, 4:37am GMT
Blindedbysound 419-781 Blinded By Sound -
H Blindedbysound Xht - Blinded By Sound
Posted: December 21st, 2021, 7:40pm GMT
H Blindedbysound Xht Blinded By Sound -
N Blindedbysound 843 - Blinded By Sound
Posted: December 21st, 2021, 5:27pm GMT
N Blindedbysound 843 Blinded By Sound -
400th Proton Therapy Patient Example of Why This Treatment Option Can Be Beneficial When Fighting Cancer - McLaren Health Care
Posted: December 21st, 2021, 11:41pm GMT
-
Blindedbysound 862-812 - Blinded By Sound
Posted: December 21st, 2021, 10:17pm GMT
Blindedbysound 862-812 Blinded By Sound -
Head and Neck Cancers - CU Anschutz Today
Posted: May 27th, 2021, 9:51pm GMT
Head and Neck Cancers CU Anschutz Today -
Overexpression of PD-L2 is associated with shorter relapse-free surviv | OTT - Dove Medical Press
Posted: June 13th, 2017, 5:00am GMT
Overexpression of PD-L2 is associated with shorter relapse-free surviv | OTT Dove Medical Press
PubMed - Acinic Cell Carcinoma
-
Head and Neck Acinic Cell Carcinoma: A New Grading System Proposal and Diagnostic Utility of NR4A3 Immunohistochemistry
Fetched: January 17th, 2022, 5:00am GMT by Bin Xu
Am J Surg Pathol. 2022 Jan 17. doi: 10.1097/PAS.0000000000001867. Online ahead of print.
ABSTRACT
Acinic cell carcinoma (AciCC) is traditionally considered as a low-grade salivary gland carcinoma. However, a subset demonstrates high-grade features with a higher mortality rate and distant metastasis. In this large retrospective study of 117 cases, we aimed to establish a histologic grading scheme for AciCC. Adverse independent prognostic factors identified on the multivariate analysis included older age, tumor necrosis, nuclear anaplasia, lymphovascular invasion, absence of tumor-associated lymphoid stroma, and high American Joint Committee on Cancer (AJCC) pT and pN stages. A 3-tiered grading scheme using 4 pathologic parameters (mitotic index, necrosis, tumor border, and fibrosis at the frankly invasive front) was subsequently applied. Compared with low/intermediate-grade, high-grade AciCC defined as a mitotic index ≥5/10 HPFs and/or necrosis was an independently adverse prognostic factor. The 5-year overall survival was 50% in high-grade AciCCs, and 100% in low-grade or intermediate-grade AciCCs. Compared with low-grade or intermediate-grade AciCC, high-grade tumors were associated with older age, larger tumor size, focal rather than diffuse zymogen granules, solid architecture, infiltrative tumor border, fibrosis at the frankly invasive front, lymphovascular invasion, perineural invasion, positive margin, high pT, and pN stages. NR4A3 was a highly sensitive and specific immunohistochemical stain for diagnosing AciCC with a sensitivity and specificity of 96% and 93%, respectively. In conclusion, although we proposed a 2-tiered grading system for AciCC with high-grade tumors defined by a mitotic count ≥5/10 HPFs and/or necrosis, more studies are needed to assess the prognostic value of intermediate grade. NR4A3 immunohistochemical stain is a useful diagnostic marker for AciCC.
PMID:35034042 | DOI:10.1097/PAS.0000000000001867
-
Cushing's syndrome due to ectopic adrenocorticotropin secretion by a parotid carcinoma
Fetched: January 15th, 2022, 5:00am GMT by Fernanda F Antonacio
Arch Endocrinol Metab. 2022 Jan 13:2359-3997000000426. doi: 10.20945/2359-3997000000426. Online ahead of print.
ABSTRACT
We report a rare case of Cushing's syndrome in a 37-year-old female who initially presented with localized acinic cell carcinoma of the parotid gland. In January 2014, she underwent a right parotidectomy with facial nerve preservation and adjuvant radiotherapy. In August 2018, she presented a histologically-proven local regional relapse. The patient was considered for salvage surgery with facial nerve sacrifice and remained with no evidence of disease. One year later the patient developed pulmonary dissemination and started to gain weight and developed facial plethora and acne on the face and upper trunk. In a physical examination, the patient presented moon face, buffalo hump, acne and stage 2 hypertension. Biochemical evaluation confirmed ACTH-dependent Cushing's syndrome. IHC for ACTH in the lung biopsy revealed strong positive staining for ACTH confirming a diagnosis of ectopic ACTH secretion by a metastatic parotid acinic cell carcinoma. Ketoconazole (600 mg/d) was started to treat the CS. In addition, as chemotherapy was initiated to treat the metastatic disease. After the fifth cycle of chemotherapy, ketoconazole was suspended and the patient remained in remission of CS for four months, when CS recurred. A unique feature of this case is related to the clinical CS relapse associated with disease progression, which needed prompt treatment with ketoconazole, resulting in a significant improvement in the patient's condition. Although rare, should be attentive for possible CS features in patients with high-grade salivary gland carcinomas, since the diagnosis of ectopic secretion of ACTH may significantly impact their management and outcomes.
PMID:35029850 | DOI:10.20945/2359-3997000000426
-
A case of pathologically complete response after preoperative chemotherapy in a pancreatic acinar cell carcinoma patient with portal vein tumor thrombosis
Fetched: January 12th, 2022, 5:00am GMT by Wataru Izumo
Clin J Gastroenterol. 2022 Jan 11. doi: 10.1007/s12328-021-01571-8. Online ahead of print.
ABSTRACT
Preoperative treatment is being proposed as a standard treatment for pancreatic ductal adenocarcinoma though few cases show a pathologically complete response. On the other hand, there is no consensus regarding preoperative chemotherapy for pancreatic acinar cell carcinoma (ACC). The present study described a rare case of ACC in the pancreatic head with portal vein tumor thrombosis (PVTT) treated with preoperative chemotherapy using modified FOLFIRINOX, which achieved a pathologically complete response. A 65-year-old man was referred for consideration of treatment strategy. Contrast-enhanced abdominal computed tomography revealed a pancreatic tumor and PVTT. The pancreatic tumor was diagnosed as ACC by an endoscopic ultrasound-guided fine-needle aspiration biopsy. Initially, the tumor was assessed as unresectable due to the presence of PVTT, and therefore, a chemotherapy using modified FOLFIRINOX was administered. After 14 courses of the chemotherapy, imaging studies revealed that the tumor and PVTT showed marked reduction in size; thus, the patient underwent pancreaticoduodenectomy with combined resection of the portal vein (PV). A pathological examination uncovered a complete degeneration of the primary tumor and the PV embolus without any residue of carcinoma. The patient did not receive adjuvant chemotherapy and survived with no evidence of recurrence for 33 months after surgery. The chemotherapy using modified FOLFIRINOX could give a complete response in patients with pancreatic ACC with PVTT.
PMID:35013933 | DOI:10.1007/s12328-021-01571-8
-
Malignant Tumors of the Palate
Fetched: January 12th, 2022, 5:00am GMT by Allen Young
2021 Oct 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan–.
ABSTRACT
Malignancies of the hard and soft palate have a wide variety of characteristics. The hard palate, a subsite of the oral cavity, comprises the palatine bone's horizontal plate and the palatine process of the maxillary bone. Its boundaries include the alveolar ridge anteriorly, the soft palate posteriorly, the nasal cavity superiorly, and the oral cavity inferiorly. The hard palate is rich in minor salivary glands with close interaction between its mucosa and the underlying periosteum. This unique composition creates a different array of malignancies compared with other oral subsites.
The soft palate, on the other hand, is a subsite of the oropharynx. It is bordered by the hard palate anteriorly, palatoglossal and palatopharyngeal muscles laterally, and the uvula posteriorly. The most common malignant tumor histologies of the hard and soft palate include squamous cell carcinoma (SCC), mucoepidermoid carcinoma (MEC), adenoid cystic carcinoma (AdCC), polymorphous low-grade adenocarcinoma (PLGA), low-grade papillary adenocarcinoma (LGPA), acinic cell carcinoma (ACC), mucosal melanoma (MM), Kaposi sarcoma (KS), and non-Hodgkin lymphoma (NHL).
-
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion
Fetched: January 11th, 2022, 5:00am GMT by Marina Gaule
JCO Precis Oncol. 2022 Jan;6:e2100400. doi: 10.1200/PO.21.00400.
NO ABSTRACT
PMID:35005993 | DOI:10.1200/PO.21.00400
-
Primary acinic cell carcinoma of the breast is associated with a poor outcome: A case report and literature review
Fetched: January 11th, 2022, 5:00am GMT by Ludivine Sarsiat
Mol Clin Oncol. 2022 Feb;16(2):43. doi: 10.3892/mco.2021.2476. Epub 2021 Dec 22.
ABSTRACT
Primary acinic cell carcinoma (AcCC) is a rare histological type of malignant breast cancer. AcCC was first identified as an entity in 1996, and since then 51 cases have been reported in the literature. The first early case reports and reviews suggested a relatively favourable prognosis for patients with AcCC; however, reports of AcCC recurrent disease have been more recently described in a subset of patients with high-grade disease. The present case report describes an unusual case of estrogen receptor-negative AcCC of the breast in a 59-year-old woman who did not respond to neoadjuvant chemotherapy (NACT), despite imaging revealing a large reduction in tumour volume. Furthermore, 14 months after NACT completion, the patient presented with disease progression comprising peritoneal involvement and linitis plastica. The patient started on first-line chemotherapy with carboplatin and paclitaxel combination, achieving a notable and prolonged response. After 2.5 years and while still on carboplatin and paclitaxel, the patient developed leptomeningeal carcinomatosis disease (LD) and died 6 weeks after LD presentation. The present report is the third case of AcCC in which cancer-associated death was registered. As studies on large series are lacking, further investigations are required to identify predictors of poor outcome. Notably, the prolonged response achieved to first-line chemotherapy suggested that platinum and taxane compounds may offer a potential therapeutic benefit for patients with AcCC. Moreover, the present case report highlights the importance of careful interpretation of follow-up imaging, as an apparent positive response to treatment may not always be a true representation of disease.
PMID:35003741 | PMC:PMC8739076 | DOI:10.3892/mco.2021.2476
-
Primary salivary acinar cell carcinoma of the parotid gland with parietal metastasis: A case report
Fetched: January 11th, 2022, 5:00am GMT by Yongkang Sun
Asian J Surg. 2022 Jan 6:S1015-9584(21)00848-4. doi: 10.1016/j.asjsur.2021.12.066. Online ahead of print.
NO ABSTRACT
PMID:35000858 | DOI:10.1016/j.asjsur.2021.12.066
-
Defining the role of systemic therapy in resectable pancreatic acinar cell carcinoma
Fetched: January 8th, 2022, 5:00am GMT by Paul R Burchard
J Surg Oncol. 2022 Jan 7. doi: 10.1002/jso.26785. Online ahead of print.
ABSTRACT
INTRODUCTION: Following resection of pancreatic acinar cell carcinoma (PACC) distant recurrence remains high. We utilized the national cancer database (NCDB) to evaluate the role of systemic therapy in early-stage resected PACC.
METHODS: We queried the NCDB registry from 2004 to 2015 for patients with pathologic stage I-IIB PACC. For each stage, patients who underwent surgery alone (SA) were compared to patients who received systemic and/or radiation therapy in addition to surgery (surgery + therapy [S + T]).
RESULTS: A total of 271 patients (101 pI, 81 pIIA, and 89 pIIB) were analyzed. Of all clinically node positive patients (n = 41), the majority (n = 32, 78%) had node-positive disease at resection (pIIB). SA was performed in 112 patients (41.3%), whereas 159 (58.7%) patients received S + T. There was no difference in overall survival (OS) between S + T and SA with respect to pI or pIIA disease. In pIIB disease, S + T was associated with improved OS compared to SA (34.9 vs. 16.9 months, p = 0.031). Single-agent chemotherapy was associated with improved OS for pIIB disease when compared to SA (hazard ratio: 0.38, 95% confidence interval: 0.16, 0.83).
CONCLUSION: In resectable PACC, the survival benefit of adjuvant therapy is limited to pathologic stage IIB disease. This benefit is evident even in patients treated with single-agent chemotherapy.
PMID:34994405 | DOI:10.1002/jso.26785
-
Low-grade triple-negative breast carcinomas. A report of 2 cases and an update of current concepts
Fetched: January 5th, 2022, 5:00am GMT by Juan Ruiz
Rev Esp Patol. 2022 Jan-Mar;55(1):26-35. doi: 10.1016/j.patol.2021.01.006. Epub 2021 Feb 27.
ABSTRACT
Triple negative breast cancer is defined by the lack of expression of estrogen, progesterone and HER2 receptors. Significant molecular, morphological and clinical heterogeneity is present in this group of neoplasms. Although the majority are high-grade tumors, low-grade triple negative breast cancers can occur and their evolution, molecular characteristics and therapeutic management vary from the former. In the current review, we focus on the histological and immunohistochemical phenotypes of two new low-grade cases: an acinic cell carcinoma and an adenoid cystic carcinoma. Data originated from the pathology department of a third-level hospital over an 18-month period, within a breast cancer screening program. Low-grade triple negative cancers should be suspected in triple negative breast cancers with low proliferative rates as, unlike high-grade tumors, they require a multidisciplinary approach. They can be diagnosed at an early stage by immunohistochemistry using core needle biopsy.
PMID:34980437 | DOI:10.1016/j.patol.2021.01.006
-
Prognostic factors in acinic cell carcinoma of the head and neck: The Amsterdam experience
Fetched: January 2nd, 2022, 5:00am GMT by Stijn van Weert
Oral Oncol. 2021 Dec 29;125:105698. doi: 10.1016/j.oraloncology.2021.105698. Online ahead of print.
ABSTRACT
INTRODUCTION: The aim was to analyse prognosticators in acinic cell carcinoma (AciCC) in two head and neck referral centers in Amsterdam, the Netherlands.
MATERIALS AND METHODS: Eighty- nine cases of AciCC treated between 1979 and 2016 were retrospectively reviewed. Five, - 10 -and 20- year estimates of survival were executed as well as univariate analysis of prognosticators.
RESULTS: The majority of AciCC were T1-T2; 89%. Two percent had nodal disease (2%). The most affected organ was the parotid gland (84%) with a female preponderance (67%). Mean age was 52 years with most cases diagnosed in the fourth to sixth decade. The majority of patients received adjuvant radiotherapy. Elective neck dissection (END) in the N0 neck showed no metastases. High grade transformation (HGT) was found in 21% of cases. Median follow up was 101.9 months. Median time to recurrence was 26 months. Nine patients developed distant metastases (DM) of whom 6 had HGT-AciCC. Median survival with DM was 7 months. Five,- ten -and twenty- year estimates were 84%, 81% and 81% for recurrence free survival respectively. Negative clinical features were advanced stage disease and tumour size > 2.6 cm. Negative histological features were a high mitotic rate, HGT, close and involved surgical margins and necrosis.
CONCLUSION: AciCC- HGT excluded- of the head and neck has an excellent prognosis and shows acceptable long term results. END can be considered as part of the standard treatment due to the relative high incidence of HGT- AciCC and low accuracy of cytology.
PMID:34973520 | DOI:10.1016/j.oraloncology.2021.105698
-
A quantitative evaluation of the histological type dependence of the programmed death-ligand 1 expression in non-small cell lung cancer including various adenocarcinoma subtypes: a cross-sectional study
Fetched: December 31st, 2021, 5:00am GMT by Kensuke Kojima
Jpn J Clin Oncol. 2021 Dec 29:hyab202. doi: 10.1093/jjco/hyab202. Online ahead of print.
ABSTRACT
The association between non-small cell lung cancer histology and programmed death-ligand 1 expression remains controversial. We retrospectively analyzed histological dependence of the programmed death-ligand 1 expression by a multiple regression analysis of 356 non-small cell lung cancer patients. The programmed death-ligand 1 expression patterns of adenocarcinoma were consistent with a pathological predominant growth pattern as a reference to papillary adenocarcinoma: minimally invasive adenocarcinoma[partial regression coefficient (B), 0.17; 95% confidence interval, 0.05-0.59], lepidic adenocarcinoma (B, 0.46; 95% confidence interval, 0.23-0.90), acinar adenocarcinoma (B, 1.98; 95% confidence interval, 1.05-3.76) and solid adenocarcinoma (B, 5.11; 95% confidence interval, 2.20-11.9). In histology other than adenocarcinoma, the programmed death-ligand 1 expression tended to be high with poor differentiation: adenosquamous carcinoma (B, 4.17; 95% confidence interval, 1.05-16.6), squamous cell carcinoma (B, 4.32; 95% confidence interval, 2.45-7.62) and pleomorphic carcinoma (B, 13.0; 95% confidence interval, 4.43-38.2). We showed quantitatively that the programmed death-ligand 1 expression in non-small cell lung cancer tended to be clearly histology-dependent, with more poorly differentiated histology showing a higher expression.
PMID:34969085 | DOI:10.1093/jjco/hyab202
-
Mammary analogue secretory carcinoma: A challenging case arising in a young man with radiation exposure
Fetched: December 26th, 2021, 5:00am GMT by Priyadharshini Sivasubramaniam
Ann Diagn Pathol. 2021 Nov 22;57:151862. doi: 10.1016/j.anndiagpath.2021.151862. Online ahead of print.
ABSTRACT
Mammary Analogue Secretory Carcinoma (MASC) is a recently described salivary gland tumor frequently sampled via fine-needle aspiration. The cytologic features of MASC are not entirely distinctive and can simulate acinic cell carcinoma, but the tumor harbors an ETV6 gene rearrangement resulting in an ETV6-NTRK3 fusion gene. We present a case of MASC arising in a 31 year old man with a history of multiple radio-embolization procedures.
PMID:34953444 | DOI:10.1016/j.anndiagpath.2021.151862
-
Lysosomal and cytoskeletal events in epithelial salivary tumours as assessed by imunohistochemistry for CD63 and HSP27
Fetched: December 25th, 2021, 5:00am GMT by Asterios Triantafyllou
Pathol Res Pract. 2021 Nov 21;229:153691. doi: 10.1016/j.prp.2021.153691. Online ahead of print.
ABSTRACT
Little attention has been paid to immunohistochemically assessed, lysosomal activities in salivary neoplasia. In an attempt to remedy this, the present investigation applied immunohistochemistry for CD63 antigen (a lysosomal membranous protein) and HSP27 (a molecular chaperone with roles in intracellular homeostasis) to archival paraffin-embedded surgical specimens of 101 benign and malignant, epithelial salivary tumours. Diffuse cytoplasmic CD63 immunoreactivity was seen in serous cells in acinic cell carcinoma, and mucous cells in mucoepidermoid carcinoma, pleomorphic adenoma (PA) and Warthin tumour. Apical rims or bands of CD63 immunoreactivity were also seen in simple cells lining tubular structures in PA, acinic cell carcinoma, mucoepidermoid carcinoma and polymorphous (low-grade) adenocarcinoma; and, occasionally, oncocytic luminal cells in Warthin tumour. HSP27 immunoreactivity was usually seen in non-luminal cells of PA, basal cells of oncocytic tumours, epidermoid cells of mucoepidermoid carcinoma and PA, and cells outlining aggregates or pseudolumina of adenoid cystic carcinoma. Expression of CD63 is preferentially associated with differentiated or simple luminal cell phenotypes in epithelial salivary tumours and possibly reflects autophagy of secretory granules or absorption of luminal material. Expression of HSP27 is preferentially associated with non-luminal cells and possibly reflects remodelling of the cytoskeleton.
PMID:34942509 | DOI:10.1016/j.prp.2021.153691
-
Diagnosis and treatment of secretory carcinoma arising from the oral minor salivary gland: Two case reports
Fetched: December 24th, 2021, 5:00am GMT by Masaru Ogawa
Medicine (Baltimore). 2021 Dec 23;100(51):e28390. doi: 10.1097/MD.0000000000028390.
ABSTRACT
INTRODUCTION: Secretory carcinoma (SC) is a malignancy of the salivary glands, which is similar to SC of the breast regarding its association with neurotrophic tyrosine receptor kinase fusion-positive gene. SC is a recently described salivary gland tumor, and there are a few reports describing oral minor salivary gland-derived SC. We reported two cases of SC in the oral cavity and reviewed the literature.
PATIENT CONCERNS: The patients included a 65-year-old Japanese woman who presented with a mass of the upper lip and an 84-year-old Japanese man who presented with a mass on the buccal mucosa.
DIAGNOSIS: Diagnosis was based on histomorphological and immunohistochemical findings and identification of a specific translocation of the ETS variant 6-neurotrophic receptor tyrosine kinase 3 gene fusion. Case 1 was finally diagnosed using reverse transcription-polymerase chain reaction with formalin-fixed paraffin-embedded tissue samples, while case 2 was diagnosed using fluorescence in situ hybridization analysis.
INTERVENTIONS AND OUTCOMES: In case 1, excisional biopsy was done and there was no recurrence observed in five-year follow-up. In case 2, tumor resection was done and there was no recurrence observed in two-year follow-up.
CONCLUSION: It is highly likely for many cases of SC to be initially diagnosed as acinic cell carcinoma (AciCC) owing to their similar histological findings. The treatment strategy for minor salivary gland-originated SC is similar to that of AciCC; however, SC is often highly malignant and involves a high risk of cervical lymph node metastasis. Thus, establishing an accurate diagnosis together with pathologists and confirming the presence of the ETS variant 6-neurotrophic receptor tyrosine kinase 3 fusion gene using genetic analysis is important.
PMID:34941172 | PMC:PMC8702035 | DOI:10.1097/MD.0000000000028390
-
Short communication: Distribution of phospholipids in parotid cancer by matrix-assisted laser desorption/ionization imaging mass spectrometry
Fetched: December 18th, 2021, 5:00am GMT by Hirofumi Kanetake
PLoS One. 2021 Dec 17;16(12):e0261491. doi: 10.1371/journal.pone.0261491. eCollection 2021.
ABSTRACT
BACKGROUND: Parotid cancer is relatively rare, and malignancy varies; therefore, novel markers are needed to predict prognosis. Recent advances in matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS), useful for visualization of lipid molecules, have revealed the relationship between cancer and lipid metabolism, indicating the potential of lipids as biomarkers. However, the distribution and importance of phospholipids in parotid cancer remain unclear.
OBJECTIVE: This study aimed to use MALDI-IMS to comprehensively investigate the spatial distribution of phospholipids characteristically expressed in human parotid cancer tissues.
METHODS: Tissue samples were surgically collected from two patients with parotid cancer (acinic cell carcinoma and mucoepidermoid carcinoma). Frozen sections of the samples were assessed using MALDI-IMS in both positive and negative ion modes, with an m/z range of 600-1000. The mass spectra obtained in the tumor and non-tumor regions were compared and analyzed. Ion images corresponding to the peak characteristics of the tumor regions were visualized.
RESULTS: Several candidate phospholipids with significantly different expression levels were detected between the tumor and non-tumor regions. The number of unique lipid peaks with significantly different intensities between the tumor and non-tumor regions was 95 and 85 for Cases 1 and 2, respectively, in positive ion mode, and 99 and 97 for Cases 1 and 2, respectively, in negative ion mode. Imaging differentiated the characteristics that phospholipids were heterogeneously distributed in the tumor regions.
CONCLUSION: Phospholipid candidates that are characteristically expressed in human parotid cancer tissues were found, demonstrating the localization of their expression. These findings are notable for further investigation of alterations in lipid metabolism of parotid cancer and may have potential for the development of phospholipids as biomarkers.
PMID:34919590 | PMC:PMC8682900 | DOI:10.1371/journal.pone.0261491
-
Incidental prostate cancer: A clinicopathological study
Fetched: December 17th, 2021, 5:00am GMT by Xiao-Die Zhou
Zhonghua Nan Ke Xue. 2021 Feb;27(2):145-149.
ABSTRACT
OBJECTIVE: To investigate the clinicopathological characteristics and prognosis of incidental prostate cancer (PCa).
METHODS: We retrospectively analyzed the clinical data and pathological characteristics of 96 cases of incidental PCa in 580 patients undergoing radical cystectomy and followed them up for prognosis.
RESULTS: The incidence rate of incidental PCa was 16.6% (96/580). The patients were 42－90 years old, with a median age of 73 years, 6 (6.2%) ≤60 and 90 (93.8%) over 60 years old. The average maximum diameter of the tumor was about 3.5 cm (range 1.0－9.0 cm). Histologically, 86 (89.6%) of the bladder cancer cases were high-grade invasive urothelial carcinoma (7 with squamous differentiation, 2 with sarcomatoid differentiation, 4 with glandular differentiation, and 1 with plasmacytoid/diffuse variant) and 7 were low-grade urothelial carcinoma, of which 1 case was poorly differentiated neuroendocrine carcinoma and 2 cases were bladder adenocarcinoma, including 1 case of signet ring cell carcinoma. All the PCa cases were classified as the histopathological type of classic acinar adenocarcinoma of the prostate, 67 (69.8%) with a Gleason score ≤ 6, and 29 (30.2%) with a Gleason score ≥ 7. Of the total number of incidental PCa cases, 32 (33.3%) were of clinical significance, and 59 (61.5%) of the patients were followed up for 1－95 (mean 28.7) months, during which 42 (71.2%) survived and 17 (28.8%) died, including 2 deaths due to non-cancer factors. No statistically significant difference was found in the median survival time between the 5 clinically significant and 10 non-clinically significant cases (P = 0.322).
CONCLUSIONS: There is a high probability of incidental PCa among bladder cancer patients aged >60 years. Standardized sampling plays an important role in detection of the malignancy. There is only a small proportion of incidental PCa cases with clinical significance, and therefore it affects less the prognosis than bladder cancer.
PMID:34914331